SanBio Co Ltd (JP:4592)
:4592
Want to see JP:4592 full AI Analyst Report?
4592 Stock Chart & Stats
¥2230.00
¥19.00(2.53%)
At close: 4:00 PM EST
¥2230.00
¥19.00(2.53%)
Day’s Range― - ―
52-Week Range¥1,173.00 - ¥3,990.00
Previous CloseN/A
Volume765.40K
Average Volume (3M)2.08M
Market Cap
¥98.35B
Enterprise Value¥97.60B
Total Cash (Recent Filing)¥2.74B
Total Debt (Recent Filing)¥1.36B
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Jun 15, 2026EPS Estimate
-6.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-50.61
Shares Outstanding78,058,880
10 Day Avg. Volume2,869,570
30 Day Avg. Volume2,080,090
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)9.94
Price to Sales (P/S)0.00
P/FCF Ratio-35.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,866.67Price Target Upside-16.29% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)-52.48
Revenue Forecast (FY)¥2.70B
Bulls Say, Bears Say
Bulls Say
Proprietary Cell-based Platform & PipelineSanBio's proprietary cell-based platform and clinical-stage pipeline (eg, SB623 for chronic traumatic brain injury) represent durable intellectual property and technical know-how. In regenerative medicine this can yield high barriers to entry and sustained market value if trials succeed and approvals follow.
Strengthened Reported SolvencyThe recent equity build and expanded assets improve the company's solvency profile and provide a clearer near-term funding buffer. Manageable debt-to-equity in 2023–2025 (~0.21–0.24) suggests balance-sheet flexibility versus the 2022 spike, which supports continued R&D investment while seeking non-dilutive options.
Evidence Of Narrowing LossesReported narrowing of losses and reduced peak cash burn imply successful cost controls or program de-risking. A sustained downward trend in operating losses strengthens runway assumptions and decreases probability of immediate emergency financing, improving the odds for executing clinical milestones.
Bears Say
No Commercial RevenueSanBio remains pre-commercial with zero recurring revenue, meaning the business lacks a scalable earnings base. Long-term viability therefore depends entirely on successful clinical development and commercialization of pipeline assets, raising binary execution risk and dependence on external capital.
Sustained Negative Operating & Free Cash FlowPersistent negative operating and free cash flow indicates structural cash burn tied to R&D and operations. Continued outflows require repeated financing, constrain investment optionality, and can force dilutive capital raises that weaken long-term shareholder economics absent a clear path to revenue.
Financing And Leverage Volatility RiskHistorical leverage volatility and recent increases in debt highlight reliance on external capital. If market conditions tighten or clinical setbacks occur, refinancing terms could deteriorate, increasing dilution or insolvency risk and limiting strategic flexibility for late-stage development or commercial launch.
SanBio Co News
4592 FAQ
What was SanBio Co Ltd’s price range in the past 12 months?
SanBio Co Ltd lowest stock price was ¥1173.00 and its highest was ¥3990.00 in the past 12 months.
What is SanBio Co Ltd’s market cap?
SanBio Co Ltd’s market cap is ¥98.35B.
When is SanBio Co Ltd’s upcoming earnings report date?
SanBio Co Ltd’s upcoming earnings report date is Jun 15, 2026 which is in 10 days.
How were SanBio Co Ltd’s earnings last quarter?
SanBio Co Ltd released its earnings results on Mar 17, 2026. The company reported -¥14.8 earnings per share for the quarter, beating the consensus estimate of -¥20.693 by ¥5.893.
Is SanBio Co Ltd overvalued?
According to Wall Street analysts SanBio Co Ltd’s price is currently Overvalued.
Does SanBio Co Ltd pay dividends?
SanBio Co Ltd does not currently pay dividends.
What is SanBio Co Ltd’s EPS estimate?
SanBio Co Ltd’s EPS estimate is -6.19.
How many shares outstanding does SanBio Co Ltd have?
SanBio Co Ltd has 78,058,880 shares outstanding.
What happened to SanBio Co Ltd’s price movement after its last earnings report?
SanBio Co Ltd reported an EPS of -¥14.8 in its last earnings report, beating expectations of -¥20.693. Following the earnings report the stock price went down -1.733%.
Which hedge fund is a major shareholder of SanBio Co Ltd?
Currently, no hedge funds are holding shares in JP:4592
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SanBio Co Ltd
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
4592 Company Deck
4592 Earnings Call
Q4 2026
0:00 / 0:00
4592 Stock 12 Month Forecast
Average Price Target
¥1,866.67
▼(-16.29% Downside)
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---